Effect of FLT3-ITD on PML/RARA degradation on ATRA treatment. (A) Western blots of hPML/RARA (P/R, arrowheaded) and vinculin (Vcl) expression in the bone marrow of P/R (top) and P/R-FLT3ki (bottom) APL untreated (UT) and ATRA-treated mice from 2 to 12 days. Antihuman PML antibody. The percentage of GFP-positive cells is indicated for each sample. (B) Immunofluorescence analysis of human PML/RARA (green, P/R) with DAPI (blue) in bone marrow cells of P/R and P/R-FLT3ki APL mice treated with ATRA after 2 and 6 days (scale bar, 10 µm). (C) Western blot analysis of RARA degradation on in vivo ATRA treatment of the indicated time in both APL models (left). Graph shows quantification of RARA/Vcl ratio, indicative of RARA degradation (right).